OA is the most common joint disorder in the world, but there are no approved therapeutics to prevent disease progression. Historically, OA has been considered a wear-and-tear joint disease, and efforts to identify and develop disease-modifying therapeutics have predominantly focused on direct inhibition of cartilage degeneration. However, there is now increasing evidence that inflammation is a key mediator of OA joint pathology, and also that the link between obesity and OA is not solely due to excessive loadbearing, suggesting therefore that targeting inflammation in OA could be a rewarding therapeutic strategy. In this review we therefore re-evaluate historical clinical trial data on anti-inflammatory therapeutics in OA patients, highlight some of the more promising emerging therapeutic targets and discuss the implications for future clinical trial design.
OA and inflammation
Inflammation in OA has been overlooked for many years. However, histological analysis, US and MRI have shown evidence of synovitis in OA joints [1] , with increased cellular infiltration of activated B cells and T lymphocytes. Histological studies indicate that synovitis is present in 50% of patients with early OA, and in nearly all patients with late-stage OA [2] . Furthermore, synovial hypertrophy as detected by US has been shown to correlate to knee OA disease severity [3] .
Several studies have reported elevated levels of a number of pro-inflammatory mediators (including TNF-a, IL-1b, IL-6, IL-15, IL-17, IL-18 and nitric oxide (NO)) in the serum or SF of OA patients [4, 5] , compared with healthy patients (Fig. 1) . Furthermore, stimulation of cartilage tissue with pro-inflammatory cytokines mimics many of the structural changes associated with OA [68] .
In light of this, it is perhaps surprising that clinical studies in OA patients with anti-inflammatory therapeutics have thus far disappointed. However, OA pathology is highly heterogeneous, with the degree of synovitis varying among patients. Indeed, synovitis is not present in half of the patients with early OA [2] . Therefore, patient selection is an important consideration for such clinical studies; unless taken into account, it could impact on whether the clinical end point is met. For this reason, we have re-evaluated the clinical trial data of anti-inflammatory therapeutics in OA (Table 1) , to highlight in particular the specific OA patient cohort studied, whether patients were selected for synovitis and the clinical end points measured. This is not a systematic review. Instead, we have focused on completed randomized control trials (RCTs) conducted during the last 10 years in patients with hand, knee and hip OA that had reported clinical end points. Second, we explored the opportunities for the development of new, targeted therapeutics (Table 2) . We discuss the requirement to stratify patients for such approaches.
Anti-inflammatory therapeutics in OA patients
Anti TNF-a therapies In OA joint tissues, SF and serum, TNF-a has been reported to be elevated compared with healthy patients [911] . In rodent models of traumatic joint injury, TNF-a expression is induced [12] and correlates to joint space narrowing (JSN) [13] . Furthermore, overproduction of TNF-a induces NO [14] and upregulates the expression of MMPs [15] , while TNF-a receptor antagonists block NO production in human cartilage tissue [16] . TNF-a has also been demonstrated to inhibit proteoglycan [17] , link protein [18] and Type II collagen synthesis. However, despite these data and the proven successes in treating RA patients with antiTNF-a therapeutics, clinical trials in OA patients have yielded conflicting and generally disappointing results.
Adalimumab (Humira; Abbott Laboratories, IL, USA) is a human mAb bioengineered to bind to TNF-a and prevent receptor binding [19] . It has been shown to be efficacious in reducing the pathological symptoms of RA in several clinical trials (DE001/003, DE004, DE007, DE009 and DE010) [19] . However, its effect on OA disease modification has not been clinically proven.
In a Phase II, 12-month RCT (NCT00296894), 60 patients with active erosive hand OA received adalimumab (40 mg) or placebo subcutaneously every 2 weeks. Progression from palpable soft tissue swelling to joint damage decreased 10-fold in the adalimumab group compared with the placebo group [20] , with a reduction in the proportion of patients experiencing a new erosive IP joint at the 12-month follow-up (26.7 vs 40% placebo control). However, these findings did not reach statistical significance, and adalimumab was deemed ineffective at reducing disease activity [20] .
In a Phase I/II study of 17 patients with knee OA (NCT00686439), adalimumab (40 mg, every 2 weeks) resulted in significant improvements in joint pain at 12 weeks with WOMAC 20% and WOMAC 50% responses in 70 and 40% of patients, respectively [21] . However, this study did not incorporate measures of disease modification including JSN, so it is unknown whether prolonged treatment with adalimumab in this patient cohort would ultimately be disease modifying. Furthermore, adalimumab failed to reach its primary end point of improving pain in a Phase II study (NCT00597623) in patients with hand OA refractory to standard-of-care analgesics [22] .
It is clear that antiTNF-a therapeutics are far less efficacious in improving OA pain and joint mobility compared with the outcomes achieved in RA patients. Indeed, RA is a more inflammatory condition, with greater evidence of TNF-a and immune cell involvement. However, some positive results have been reported with adalimumab in patients with knee OA and in patients with erosive hand OA. It should be stressed that these clinical studies did not measure disease progression, and likely involved highly heterogeneous OA patient cohorts. Despite several pilot studies (NCT01144143) [ 
FIG. 1 The relationship between joint inflammation and OA pathology
Cartilage degradation and fragmentation causes synovial inflammation, and increases production of pro-degradative (MMPs) and pro-inflammatory (IL-6, IL-7, IL-1b, IL-15, IL-17, TNFa) proteins. Synovium immune cell infiltration and obese adipose tissue contribute towards increased production of pro-inflammatory cytokines and thus increase the production of proteolytic enzymes, which drive further cartilage breakdown. Light blue ovals represent current and potential drugs and their associated targets. Red and blue spheres, and purple cloud shapes represent immune cells, including B cells, T cells and macrophages. NO: nitric oxide; PGE2: prostaglandin E2; TLR: Toll-like receptor. TLR2 mAbs reduce disease score in CIA model [99] TLR4 Activated by DAMPS in OA SF. Expression high in areas of cartilage damage [92] , and increases with JSN progression [93] Activation promotes cytokine production in human chondrocytes [147] . Nonspecific TLR4 inhibitors reduce procatabolic effects in chondrocytes [91, 95] TLR4 KO mice protected against IL1bmediated OA [147] . Non-specific TLR4 inhibitors protective against cartilage loss in murine OA model [96] Adipokines Leptin Elevated in OA serum or SF [109] . Correlation between serum levels and cartilage loss at 2 years [148] Induces production of MMPs [110] and proinflammatory cytokines [111] Alternative IL-1 pathway inhibitors such as the human mAb AMG108 have been designed to directly target the IL-1 receptor. In a RCT (NCT00110942) of 160 patients with knee OA, AMG108 was well tolerated, independent of dosage or route of administration. However, although marginal improvements in pain were noted in the AMG108 group, the difference was statistically insignificant and the clinical end point was not achieved [41] .
Given the limited clinical efficacy from subcutaneous administration of IL-1b inhibitors and the potential for adverse systemic events, recent studies have focused on IA administration [42] . A RCT (NCT00110916) involving 170 patients with painful knee OA administered either 50 mg or 150 mg of anakinra (A IL-1b receptor antagonist), or placebo control. Unfortunately, no improvement in WOMAC score or cartilage turnover was reported after 4 weeks [43] . However, patients were not pre-selected on the basis of any confirmed synovitis. Thus, it is possible that the study population contained a heterogeneous mix of responders and non-responders.
Arachidonic acid pathway inhibitors
NSAIDs are often prescribed to reduce OA pain [44] . Pharmacologically they inhibit cyclooxygenase (COX) enzymes in the arachidonic acid pathway, leading to a reduction in prostaglandin synthesis (prostaglandins are known mediators of pain and inflammation). Non-selective NSAIDs (nsNSAIDs) (e.g. ibuprofen, naproxen and diclofenac) inhibit both COX-1 and COX-2 enzymes, and their efficacy in reducing pain, inflammation and swelling in patients with OA has been demonstrated in several clinical studies (NCT01461369, NCT01860833) [4547] .
Critically, long-term administration of nsNSAIDs is associated with significant adverse events, from gastrointestinal (GI) perforation, ulceration and bleeding [48] due to the reduction of GI tract protective prostanoids (a process mediated by COX-1) [49] . Due to these issues, selective COX-2 inhibitors have been developed, including celecoxib and valdecoxib.
In a RCT (NCT00650624), valdecoxib (5, 10 and 20 mg daily dosage) was compared with the nsNSAID naproxen (500 mg twice-daily dosage) in patients with moderate/ severe knee OA. At 5 and 10 mg doses, the valdecoxib group exhibited significantly reduced GI toxicity compared with the naproxen group [50]. Unfortunately, although clinical trials demonstrated a reduction in GI complications [51, 52] , an increased risk of adverse cardiovascular events was noted [53] . This is attributed to the mode-of-action of selective COX-2 inhibitors, which decrease prostacyclin production without altering thromboxane levels.
An alternative approach is dual inhibition of leukotrienes and prostaglandins, by targeting both 5-lipoxygenase (LOX) activity and COX-2. One such COX/LOX inhibitor is licofelone (Merckle GmbH). In preclinical models of OA, licofelone has shown disease-modifying efficacy in reducing synovium hypertrophy, cartilage lesions and production of pro-inflammatory PGE2 and leukotrienes B4 [54, 55] .
Licofelone was shown to significantly reduce cartilage volume loss (vs nsNSAID alone) in a recent RCT of patients with knee OA [56] . Specifically, 355 knee OA patients received twice-daily naproxen (500 mg) or licofelone (200 mg). Cartilage volume and JSN was measured at baseline, 6, 12 and 24 months [56] . Global cartilage loss was significantly less in the licofelone group compared with the naproxen group [56] . Critically, no reported GI or cardiovascular toxicity at efficacious concentrations were recorded [57] .
Despite these promising results, licofelone has not yet been submitted for regulatory approval. There is evidence to suggest that the rate of OA progression may increase in patients receiving long-term NSAID treatment. Radiological assessment of knee and hip OA progression found an increase in the risk of OA progression in individuals on long-term diclofenac treatment (>180 days) compared with individuals on short-term treatment (130 days) [58] . Indeed, in contrast to their efficacy in blocking proinflammatory responses, COX2 inhibitors have been reported to delay the resolution of inflammation in chronic inflammatory preclinical models [59] . Whether these data are the reason why licofelone has not progressed since its positive Phase III data is unclear.
NO inhibitors
NO plays an important role in inflammatory processes and is considered a key mediator of cartilage destruction in OA [60] . NO and the inducible NO synthase (iNOS) are upregulated in preclinical animal models of OA [61] as well as in human OA chondrocytes [62] , and mediate the release of pro-inflammatory cytokines. Indeed, NO can mediate many of the pathogenic effects of IL-1b through the activation of MMPs, the inhibition of proteoglycan and collagen synthesis, and the enhancement of inflammation [63] . Preclinical studies have shown that iNOS knockout mice are resistant to development of OA [64] and that pharmacological inhibition of iNOS reduces OA progression and pain in the monosodium iodoacetate (MIA) rodent of OA [65] and in a canine model of OA [66] .
A recent clinical trial investigated the safety and efficacy of a novel irreversible iNOS inhibitor (SD-6010) on slowing OA progression in a cohort of overweight and obese patients with knee OA (NCT00565812). Disappointingly, although the iNOS inhibitor was well tolerated, the drug failed to slow the rate of JSN vs placebo over a course of 96 weeks [67] . However, additional iNOS inhibitors are in development, including S-methylisothiourea, which in preclinical models is effective in reducing NO and disease progression in the MIA rodent model of OA [65] . Whether this promising preclinical data translates into human efficacy is a critical question, but these are encouraging studies.
Emerging anti-inflammatory drug targets
Since efforts to develop effective disease-modifying OA therapeutics against prime inflammatory drug targets have yet to bear fruit, ongoing research to better www.rheumatology.oxfordjournals.org understand the inflammatory response in OA joint tissues is critical so that new drug targets can be identified. There are a number of different therapeutic approaches being investigated that may ultimately provide an effective antiinflammatory therapeutic for OA patients, including nonpharmacological approaches such as nutraceuticals and gene therapy [68] . Below we summarise some of the promising emerging targets, based on their disease linkage to OA and available preclinical data.
Synovitis-associated cytokines
In addition to TNF-a and IL-1b, many additional cytokines and chemokines, detectable in both the SF and in serum, have also been associated with OA [69] . One notable example is IL-15, which has been associated with RA pathology. However, IL-15 may also play an important role in early OA, since IL-15 expression in SF [70] and in serum are associated with the progression of early knee OA [71] and pain [72] . Similarly, IL-7 has been implicated in joint inflammation [73] , since studies have shown it can mediate TNF-a production in the RA joint [74] . Importantly, recent studies have shown that IL-7 is expressed by articular chondrocytes and that IL-7 stimulation of cartilage induces MMP13 production and proteoglycan loss [75] .
Critically, whether these inflammation-associated cytokines are central regulators of early OA disease pathology or purely biomarkers of an inflammatory tissue is an important question. This will require target validation studies in appropriate and translatable preclinical models, as well as in human ex vivo tissues. One of the prime candidates for such studies is IL-17, since IL-17A polymorphisms correlate to OA susceptibility in particular patient cohorts [76] . In knee OA, IL-17 is elevated in both the serum and SF, and correlates with KellgrenLawrence (KL) grade [77] . In vitro human chondrocyte studies have shown IL-17 stimulates the production of NO and MMPs [78] , and decreases TIMP-2 and TIMP4 expression [79] . Given these data, studies that aim to modulate IL-17 expression or its signalling activity in appropriate models are an important next step.
p38 pathway inhibitors
There is good evidence that the p38 MAPK signalling pathway is activated in OA, and is a prominent pathway that mediates pro-inflammatory cytokine signal transduction. In human OA articular cartilage, p38 is phosphorylated by several putative drivers of OA, including IL-1b, TNFa and damage-associated molecular patterns (DAMPs), such as fibronectin fragments [80, 81] . Furthermore, p38 inhibitors have shown efficacy both in reducing cartilage degeneration in the MIA OA model [8284] , and reducing pain in RA animal models [85] .
Clinically, a p38 inhibitor (PH-797804) is currently being tested for its analgesic efficacy when administered orally in patients with knee OA KL grade <2 (NCT01102660). However, due to the cell-typedependent pro-inflammatory and anti-inflammatory functions of p38 MAPK [86] , systemic delivery of p38 inhibitors may not be appropriate. An alternative approach is to develop therapeutics that target molecules downstream in the p38 MAPK pathway, thus providing a more selective targeting approach.
MAPKAPK2 (MK2) is one of several kinases directly activated by p38 [87] , and is known to post-transcriptionally regulate transcripts containing adenine-rich elements [88] , including TNF-a and MMP-13. We have previously shown that MK2 is active in areas of cartilage damage, and that MK2 inhibition is as effective as p38 inhibition in preventing the IL-1bmediated secretion of PGE2 and MMPs [89] . The in vivo efficacy of MK2 inhibition in OA preclinical models has not yet been reported, but MK2 inhibitors have shown efficacy in an inflammatory bowel murine model [90] .
Toll-like receptors
Several DAMPs are associated with OA, including cartilage extracellular matrix fragments and plasma proteins that enter the SF. Binding of DAMPs to pattern-recognition receptors such as Toll-like receptors (TLRs) can activate NFOEB-mediated inflammatory signalling. Articular chondrocytes have been shown to express TLR1-9 [91] , but studies on TLR4 have so far provided the strongest link to OA. In humans, TLR4 expression is associated with areas of cartilage damage [92] , JSN [93] and the expression of proinflammatory cytokines, including IL-1b, TNFa, PGE2 and NO [94] . Multiple agents that either bind to TLR4 agonists (e.g. Pep-1), or modulate TLR4 signalling (e.g. PPARdelta and BMP-7) can inhibit pro-inflammatory and pro-catabolic effects in chondrocytes [91, 95] and prevent cartilage loss in a murine model of OA [96] . Therefore, development of specific pharmacological TLR4 inhibitors may be of therapeutic value.
A number of studies have also examined the role of TLR2 in OA. Similarly to TLR4, its expression is associated with lesional areas of cartilage damage [92] , and several reports have demonstrated that TLR2 stimulation induces the production of pro-inflammatory cytokines [9799] and cartilage degradation [92] . However, in vivo modulation of TLR2 in arthritic joint models has revealed conflicting results. Of concern, TLR2 knockout mice develop a more severe OA pathology [100] , which could be due to compensatory developmental effects that have yet to be established. More promisingly, TLR2 mAbs have been shown to inhibit both the production of pro-inflammatory cytokines and reduce the development of arthritis in the CIA model [99] . The therapeutic utility of such TLR2 mAbs in OA-specific models has not yet been reported.
Adipose-secreted cytokines
The discovery that adipose tissue secretes cytokines (adipokines) has led to the current understanding of adipose tissue as an endocrine organ [101] . Adipokine release has been mechanistically linked to metabolic complications and the metabolic syndrome [102, 103] by contributing to the low-level pro-inflammatory state seen commonly in obese individuals [104, 105] .
Critically, adipokine signalling is now receiving much attention in relation to OA joint pathophysiology, largely due to the association between obesity and OA [104, 106] in both weight-bearing and nonweight-bearing joints (e.g. hands) [107] . Furthermore, differential expression of particular adipokines has been reported in OA serum and SF, which are capable of modulating cartilage catabolic and anabolic pathways [106] .
One of the most widely studied adipokines is leptin, a product of the ob gene, which is known to regulate metabolism and appetite [108] . Leptin is increased in OA SF compared with non-OA SF controls [109] . Recombinant leptin, either alone or synergistically with IL-1b, induces MMP-1 and MMP-13 expression in primary human chondrocytes [110] , and increases the production of inflammatory mediators, including IL-1b, IL-6, IL-8 and PGE2 [111] . Due to the pro-inflammatory nature of leptin and its potential to drive cartilage catabolism, the recent development of peptidebased and antibody-based leptin antagonists could provide an effective therapeutic [112, 113] .
RNAi-based therapeutics RNA interference (RNAi)based therapeutics such as siRNAs represent a relatively new and largely untapped avenue of therapeutic potential [114] . Relatively cheap to design and produce, this class of therapeutic is highly attractive to drug discovery [115] .
One of the greatest hurdles for siRNA therapeutics development is achieving successful in vivo delivery to the site of action. Unless protected, for example by complexing with cationic lipids, siRNAs rapidly degrade in serum [116] . Successful preclinical studies using naked siRNAs have predominantly been achieved in cases where systemic delivery can be avoided, such as in airway disease models [117] , or in ocular conditions where the siRNA can be delivered directly to the site of action [118] .
Systemic in vivo delivery of anti-inflammatory siRNAs has produced positive results in preclinical models of inflammatory joint disease where cationic lipids have been utilized as delivery vehicles. For example, reduced arthritis disease severity has been reported in the CIA murine RA model using cationic lipids to deliver siRNA targeting TNFa [119] and siRNA targeting a panel of pro-inflammatory mediators (including TNFa, IL-1b, IL-6, IL-18 and cytosolic phospholipase A2a) [120] . In addition, IA delivery of virally packaged siRNAs targeting TNFa have shown disease-modifying efficacy in the murine CIA RA model, and similarly siRNA targeting NFOEB in the rodent meniscus tear OA model [121] .
Optimization of the delivery of RNAi-based therapeutics into the joint is required, together with a greater understanding of their specificity, before their utility as OA therapeutics can be fully realised. However, given that a limited proportion of targets are considered tractable with either small molecule or mAb entities, this field represents a highly important one. Furthermore, since Next Generation Sequencing has now identified multiple families of non-coding RNAs (e.g. mRNA and long intergenic non-coding RNAs (lincRNAs) [122, 123] , the number of potential targets for therapeutic intervention is set to markedly increase. Importantly, several of these noncoding RNAs have already been shown to regulate chondrocyte inflammatory responses [124] .
Stratification of OA patients for anti-inflammatory therapeutics
Critically, for clinical trials of anti-inflammatory therapeutics, synovitis is not reported to be present in all patients with early OA. However, one cohort where synovitis is believed to play a central role is post-traumatic OA, which is reported to account for 12% of symptomatic OA of the hip, knee and ankle [125] . Electron microscopy analysis suggests that trauma induces a differential synoviocyte configuration compared with primary OA synovitis [126] , and increased cytokine expression has been documented after joint trauma in chondrocytes, synoviocytes, infiltrating immune cells and SF [31, 127, 128] .
Gender may also be an important factor to consider for trials of particular OA anti-inflammatory therapeutics. There are no large cohort studies that have reported differences in the degree of synovitis between male and female patients with OA using modern imaging techniques. However, such imaging techniques cannot determine differences in individual inflammatory mediators. For example, free levels of leptin have been reported to be higher in the joints of females with knee OA, compared with in males [129] . This finding could explain why the association between obesity and OA risk is reported to be greater in females [130] , and suggests that therapeutics targeting leptin signalling could be more efficacious in female OA patients. Furthermore, a longitudinal prospective follow-up study found that females exhibited a greater incidence of poly-articular OA, more rapid structural progression, and a more severe symptomatic disease [131] . The higher incidence of multi-joint involvement in females with hip OA could indicate the presence of a systemic inflammatory OA driver that is not present to the same degree in males [131] . In addition, the increase in incidence of OA in females rises dramatically post menopause [132, 133] , with retrospective casecontrol studies demonstrating a protective and anti-inflammatory role of oestrogen in OA [134136] . Indeed, in vitro studies have shown that oestrogens enhance glucosaminoglycan synthesis [137] , inhibit COX2 mRNA expression [138] and protect against TNF-a, oncostatin-M [139] and reactive oxygen speciesinduced damage [140] . Furthermore, modulation of oestrogen signalling is itself a potential target for developing a therapeutic. However, oestrogen receptor a or b agonists have failed to demonstrate anti-inflammatory efficacy in patients with RA [141] .
This knowledge of the diverse OA patient population necessitates the requirement for clear patient stratification in clinical trials. The impact of not selecting the appropriate patient population was illustrated by clinical trials with the drug Iressa (AstraZeneca), an epidermal growth factor receptor (EGFR)-targeted therapy for nonsmall cell lung cancer patients. Iressa originally failed to meet its clinical end point during a Phase II trial. However, subsequent analysis showed those patients with an EGFR mutation [142] had improved survival. Not selecting the appropriate patient population masked the beneficial effect of the drug www.rheumatology.oxfordjournals.org in the original clinical study. Iressa was eventually approved 5 years after the original Phase III trial and several large costly follow-up clinical studies [142] . An important step towards identifying such clinical patient-selection biomarkers for clinical trials of OA anti-inflammatory therapeutics was recently made by Ruston and colleagues [143] , who identified a subgroup of hip OA patients that are epigenetically and transcriptomically predisposed to a cartilage inflammatory phenotype due to demethylation of the promotors of inflammatory/immunity-related genes.
Conclusions
Increasing evidence that inflammation contributes to OA joint pathology, particularly in specific patient cohorts, places great importance on both the identification of new drug targets that mediate inflammation in the joint and the requirement to re-evaluate historical clinical trial data. Preclinical studies have identified several promising targets for potential therapeutic development, and further opportunities will likely arise in the near future from new drug classes (such as RNA interference (RNAi) therapeutics) and from the re-purposing of candidate drugs from other therapeutic research areas.
Critical in the development of any future anti-inflammatory therapeutic will be the need to identify and select the appropriate patient cohort. Our review of the historical clinical trial data of anti-inflammatory therapeutics in OA patients reveals that trials have not selected or stratified patients on the basis of synovitis or other inflammatory biomarker measurements. As such, some of these reagents may be worth revisiting in the clinic in the context of an appropriately selected patient cohort. Ideally, in such cases a specific genomic or proteomic patient-selection biomarker would be identified that is closely linked to the mechanism of action of the therapeutic being tested. In the absence of such a specific biomarker, it would appear pertinent to select patients on the basis of overt synovitis from either MRI or imaging analysis of the joint. Such an approach will result in smaller and cheaper clinical trials, with a much greater chance of observing beneficial effects, and ultimately be the route to the development of a personalised OA therapeutic. 
